Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx Investment In Novel Oral Care Product Drags Down Q2 Income

This article was originally published in The Tan Sheet

Executive Summary

Matrixx Initiatives' second-quarter profits were impacted by higher R&D expenditure on a new oral care product that offers a "very unique delivery system," the firm announced during an earnings call July 25

You may also be interested in...



Late cold season impacts sales

Zicam manufacturer Matrixx Initiatives announces Dec. 11 it does not expect net sales and net income to reach the lower end of its previously announced guidance due to a slow start to the 2006/2007 cold season. The Phoenix-based company says the overall season-to-date incidence level is around 3% below last year and is negatively affecting its net sales growth. Matrixx Initiatives President & CEO Carl Johnson says, "Generally this trend would indicate a late cold season that should peak in the first quarter of 2007." In July, the firm announced it is developing a new oral care product offering a "very unique delivery system." It has not announced when the new product will be introduced (1"The Tan Sheet" July 31, 2006, p. 11)...

Late cold season impacts sales

Zicam manufacturer Matrixx Initiatives announces Dec. 11 it does not expect net sales and net income to reach the lower end of its previously announced guidance due to a slow start to the 2006/2007 cold season. The Phoenix-based company says the overall season-to-date incidence level is around 3% below last year and is negatively affecting its net sales growth. Matrixx Initiatives President & CEO Carl Johnson says, "Generally this trend would indicate a late cold season that should peak in the first quarter of 2007." In July, the firm announced it is developing a new oral care product offering a "very unique delivery system." It has not announced when the new product will be introduced (1"The Tan Sheet" July 31, 2006, p. 11)...

Late cold season impacts sales

Zicam manufacturer Matrixx Initiatives announces Dec. 11 it does not expect net sales and net income to reach the lower end of its previously announced guidance due to a slow start to the 2006/2007 cold season. The Phoenix-based company says the overall season-to-date incidence level is around 3% below last year and is negatively affecting its net sales growth. Matrixx Initiatives President & CEO Carl Johnson says, "Generally this trend would indicate a late cold season that should peak in the first quarter of 2007." In July, the firm announced it is developing a new oral care product offering a "very unique delivery system." It has not announced when the new product will be introduced (1"The Tan Sheet" July 31, 2006, p. 11)...

Topics

UsernamePublicRestriction

Register

PS099610

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel